Last edition
News about " Sanjay Gurunathan"
US FDA Approves GSK's AREXVY for At-Risk Adults Aged 18 to 49 Years
The US FDA has approved GSK’s RSV vaccine, AREXVY, for adults aged 18–49 who are at increased risk of severe RSV infection, expanding protection to an estimated 21 million at-risk individuals in this age group.
Sanjay Gurunathan | 16/03/2026 | By News Bureau | 101
European Commission Expands GSK's RSV Vaccine Arexvy to Adults Aged 18 and Above
GSK’s RSV vaccine Arexvy receives European approval for adults aged 18 plus, marking a major expansion in protection against RSV-related respiratory illness across the region.
Sanjay Gurunathan | 28/01/2026 | By News Bureau | 136
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy